Mr. Sekhri has more than 25 years of operational experience in the industry, including business development, business strategy, general management, drug development, and commercial strategy. Mr. Sekhri most recently served as operating partner and head, Biotech Ops Group at TPG Biotech, the life science arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri founded and was president and chief executive officer of Cerimon Pharmaceuticals, focused on autoimmune diseases and pain management. Prior to that, he was president and chief business officer of Ariad Pharmaceuticals. He also held senior positions at Novartis Pharma AG, and managerial roles at Millipore Corp. and PerSeptive Biosystems.
“Paul brings outstanding business development and operating experience in the life sciences industry, including with biotechnology, pharmaceutical and generic companies,” said Dr. Levin. “While we remain disciplined in our use of resources, we are committed to secure significant opportunities in key capabilities, generics and specialty medicines through our Constellation strategy. An appropriately targeted and aggressive business development strategy is central to Teva’s approach to sustainable growth.”